Filtros de búsqueda

Lista de obras de Francisco J Esteva

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

artículo científico publicado en 2003

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

artículo científico publicado en 2017

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β

artículo científico publicado en 2018

A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer

artículo científico publicado en 2019

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.

artículo científico publicado en 2018

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.

artículo científico publicado en 2007

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

artículo científico publicado en 2006

Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.

artículo científico publicado en 2012

An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.

artículo científico publicado en 2015

An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

artículo científico publicado en 2013

Antibody-drug conjugates in triple negative breast cancer

artículo científico publicado en 2018

Are Biosimilars the Future of Oncology and Haematology?

scientific article published on 01 October 2019

Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?

artículo científico publicado en 2006

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials

artículo científico publicado en 2010

Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

artículo científico publicado en 2002

B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells

artículo científico publicado en 2006

Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer ⬇️

artículo científico publicado el 1 de octubre de 2003

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors

artículo científico publicado en 2014

Blood peptidome-degradome profile of breast cancer

artículo científico publicado en 2010

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

scientific article published on 15 February 2019

Breast carcinoma treatment received by women with disabilities compared with women without disabilities.

artículo científico publicado en 2002

CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.

artículo científico publicado en 2015

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

artículo científico publicado en 2017

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

artículo científico publicado en 2008

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer

artículo científico publicado en 2002

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy

artículo científico publicado en 2003

Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer

artículo científico publicado en 2013

Circulating tumor cell analysis in metastatic triple-negative breast cancers

artículo científico publicado en 2014

Clinical development of CT-P6 in HER2 positive breast cancer

artículo científico publicado en 2019

Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma

artículo científico publicado en 2015

Clinical utility of gene-expression signatures in early stage breast cancer

artículo científico publicado en 2017

Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?

scientific article published on 01 April 2008

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes

artículo científico publicado en 2014

Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.

artículo científico publicado en 2006

Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

scientific article published on 01 August 2019

Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

artículo científico publicado en 2003

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer

artículo científico publicado en 2017

Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer

artículo científico publicado en 2006

Early breast cancer

artículo científico publicado en 2009

Effect of HER2 status on distant recurrence in early stage breast cancer

artículo científico publicado en 2012

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

artículo científico publicado en 2014

Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer

artículo científico publicado en 2014

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

scientific article published on 28 February 2019

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

scientific article published on 19 August 2019

Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study

artículo científico publicado en 2019

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6

artículo científico publicado en 2018

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer ⬇️

artículo científico publicado el 15 de diciembre de 2012

Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy

artículo científico publicado en 2005

Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.

artículo científico publicado en 2012

Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer

artículo científico publicado en 2009

Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer

artículo científico publicado en 2004

Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.

artículo científico publicado en 2017

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.

artículo científico publicado en 2018

Gaining ground on breast cancer

artículo científico publicado en 2008

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors

artículo científico publicado en 2003

Gene signature-guided dasatinib therapy in metastatic breast cancer.

artículo científico publicado en 2014

Genome-based risk prediction for early stage breast cancer

artículo científico publicado en 2014

Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis.

artículo científico publicado en 2015

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.

artículo científico publicado en 2017

Growth factor receptors in breast cancer: potential for therapeutic intervention.

artículo científico publicado en 2003

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer ⬇️

artículo científico publicado en 2014

HER-2-targeted therapy: lessons learned and future directions.

artículo científico publicado en 2003

HER2 therapy: molecular mechanisms of trastuzumab resistance.

artículo científico publicado en 2006

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

artículo científico publicado en 2014

Her2-positive breast cancer: herceptin and beyond.

artículo científico publicado en 2008

Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells

artículo científico publicado en 2002

Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis ⬇️

artículo científico publicado el 10 de agosto de 2011

High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts

artículo científico publicado en 2018

Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.

artículo científico publicado en 2013

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy

artículo científico publicado en 2015

Immunotherapy and targeted therapy combinations in metastatic breast cancer

artículo científico publicado en 2019

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

artículo científico publicado en 2003

Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

artículo científico publicado en 2014

Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.

artículo científico publicado en 2003

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy

artículo científico publicado en 2007

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.

artículo científico publicado en 2001

Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma

artículo científico publicado en 2004

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

artículo científico publicado en 2007

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

artículo científico publicado en 2020

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer

artículo científico publicado en 2019

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

artículo científico publicado en 2006

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model

artículo científico publicado en 2011

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

artículo científico publicado en 2009

Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study

artículo científico publicado en 2003

Monoclonal antibody-based targeted therapy in breast cancer.

artículo científico publicado en 2005

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer

artículo científico publicado en 2003

Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.

artículo científico publicado en 2008

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

artículo científico publicado en 2008

Neoadjuvant chemotherapy

scientific article published on 01 January 2004

Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)

scientific article published on 01 January 2007

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale

artículo científico publicado en 2005

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

artículo científico publicado en 2019

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

artículo científico publicado en 2004

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

artículo científico publicado en 2004

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

artículo científico publicado en 2010

Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response.

artículo científico publicado en 2004

Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.

artículo científico publicado en 2017

Pertuzumab in the treatment of HER2+ breast cancer.

artículo científico

Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma

artículo científico publicado en 2004

Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer

artículo científico publicado en 2003

Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule

artículo científico publicado en 2009

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer

artículo científico publicado en 2012

Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.

artículo científico publicado en 2008

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

artículo científico publicado en 2011

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer

artículo científico publicado en 2002

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

artículo científico publicado en 2002

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

scientific article published on 03 June 2018

Planning cancer control in Latin America and the Caribbean

artículo científico publicado en 2013

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

artículo científico publicado en 2011

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

artículo científico publicado en 2007

Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis

artículo científico publicado en 2018

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

artículo científico publicado en 2005

Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process.

artículo científico publicado en 2018

Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma

artículo científico publicado en 2004

RNF11 sequestration of the E3 ligase SMURF2 on membranes antagonizes SMAD7 down-regulation of transforming growth factor β signaling

artículo científico publicado en 2017

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update

artículo científico publicado en 2018

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

artículo científico publicado en 2014

Residual risk of breast cancer recurrence 5 years after adjuvant therapy

artículo científico publicado en 2008

Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

artículo científico publicado en 2011

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

artículo científico publicado en 2008

Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer

artículo científico publicado en 2012

Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer

artículo científico publicado en 2011

Signal transduction inhibitors in the treatment of breast cancer.

artículo científico publicado en 2003

Speech prosthesis aspiration.

artículo científico publicado en 2012

Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

artículo científico

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update

scientific article published on 25 June 2018

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline

artículo científico

Tamoxifen-related vasculitis

artículo científico publicado en 2006

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

artículo científico publicado en 2004

The current status of docetaxel for metastatic breast cancer.

artículo científico publicado en 2002

The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.

artículo científico publicado en 2005

The use of HER2 modulation in the adjuvant setting.

artículo científico publicado en 2007

Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out.

artículo científico publicado en 2009

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer

artículo científico publicado en 2018

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition

artículo científico publicado en 2018

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

artículo científico publicado en 2001

What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda